Literature DB >> 32285337

A stricter control of low-density lipoprotein is necessary for thrombosis reduction in "lower thrombosis risk" patients with atrial fibrillation: a multicenter retrospective cohort study.

Weizhuo Liu1, Nanqing Xiong1, Kun Xie1, Bangwei Wu1, Zhiyong Qi2, Peng Zhou1, Wen Gao1, Liwen Bao1, Xiufang Gao1, Zhaohui Qiu3, Hui Gong4, Guibin He5, Bin Cao6, Haiming Shi1, Xinping Luo7, Jian Li8.   

Abstract

Patients with atrial fibrillation (AF) are associated with increased thrombotic events. Our previous case-control study showed low-density lipoprotein cholesterol (LDL-C) was an independent predictor of ischemic stroke in AF patients. To investigate the risks of thrombosis in relation to LDL-C among AF patients at different stroke risks by long-time follow-up. Atrial fibrillation patients without history of thrombosis enrolled from five hospitals were classified into low-risk (LR) and high-risk (HR) group according to CHA2DS2VASc score and followed up with a median period of 26 months. Univariate and multivariate logistic regression analysis were performed in each group. The best cut-off value calculated by receiver operating characteristic (ROC) analysis was used to divide patients into low LDL-C (L-LDL) and high LDL-C (H-LDL) subgroups. Propensity score matching (PSM) and inverse probability of treatment weighted (IPTW) were utilized in both subgroups, after which Kaplan-Meier curves for thrombosis were performed. Univariate and multivariate analysis showed LDL-C was significantly related to thrombosis in LR, but less significantly in HR group. The best cut-off value was 2.155 mmol/L in LR and 2.795 mmol/L in HR group. Lower LDL-C was associated with decreased thrombosis in both groups by PSM and IPTW. Kaplan-Meier curves displayed that H-LDL subgroup was at higher thrombosis risk with significant difference at 24th month in LR patients. LDL-C independently predicts thrombosis with different cut-off values in AF patients at different risks. A stricter control of LDL-C level is necessary for thrombosis reduction in patients with lower score.

Entities:  

Keywords:  Atrial fibrillation; CHA2DS2VASc score; LDL-C; Thrombosis

Year:  2020        PMID: 32285337     DOI: 10.1007/s11239-020-02110-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  3 in total

1.  Left Atrial Appendage Thrombus in Patients with Nonvalvular Atrial Fibrillation before Catheter Ablation and Cardioversion: Risk Factors beyond the CHA2DS2-VASc Score.

Authors:  Yangwei Cai; Qingsong Xiong; Shaojie Chen; Xi Jiang; Jia Liao; Weijie Chen; Lili Zou; Lei Su; Yefeng Zhu; Yuehui Yin; Zhiyu Ling
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-30

2.  Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study.

Authors:  Jie Song; Xiaoxue Zhang; Meng Wei; Yakun Bo; Xianhui Zhou; Baopeng Tang
Journal:  Lipids Health Dis       Date:  2022-08-25       Impact factor: 4.315

Review 3.  Relationship between lipoproteins, thrombosis, and atrial fibrillation.

Authors:  Wern Yew Ding; Majd B Protty; Ian G Davies; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.